Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2025-12-29 @ 1:30 PM
Study NCT ID:
NCT06331832
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-03-26
First Post:
2024-03-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Sponsor:
IGM Biosciences, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
2323-EAP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None